- Published on
Infectious disease and microbiology – Neuropathies, infectious
Infectious neuropathies refer to inflammation or dysfunction of peripheral nerves caused by infectious agents or their toxins, including viruses, bacteria, parasites, and toxin-mediated mechanisms. A key example is Guillain-Barré syndrome (GBS), an immune-mediated neuropathy often triggered by a preceding infection. GBS has an incidence of approximately 1.2–3 cases per 100,000 people and can occur at any age, with peaks in young adults and older individuals. Risk factors vary depending on the cause and include immunosuppression (e.g., HIV/AIDS), advanced age, and exposure to endemic infections such as Lyme disease, leprosy, or Chagas disease. Preventive measures include vaccination (e.g., zoster, rabies, tetanus) and, in specific situations like tick exposure, prophylactic antibiotics.
The pathophysiology differs by condition but often involves either direct infection of nerve tissue or immune-mediated damage. In GBS, a prior infection triggers an immune response that cross-reacts with peripheral nerve components, leading to demyelination (most common) or axonal injury. Infectious causes include viruses such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and HIV; bacteria such as Borrelia burgdorferi (Lyme disease) and Mycobacterium leprae (leprosy); parasites like Trypanosoma cruzi; and toxins from organisms such as Clostridium botulinum and Corynebacterium diphtheriae. Additionally, many cases of GBS are preceded by infections like Campylobacter jejuni, respiratory viruses, or gastrointestinal illnesses.
Clinical presentation depends on the underlying cause. Viral neuropathies often present with pain and dermatomal rashes, as seen in herpes zoster, or progressive sensory and motor deficits, as in CMV or HIV-related neuropathies. Bacterial causes such as Lyme disease may produce cranial nerve palsies, meningitis, or radiculopathy, while leprosy leads to sensory loss and nerve thickening. Toxin-mediated neuropathies have distinctive features, such as descending paralysis in botulism or muscle spasms in tetanus. In contrast, GBS typically begins with ascending symmetric weakness starting in the lower limbs, progressing over days to weeks and potentially involving respiratory muscles and autonomic dysfunction.
Diagnosis relies on clinical evaluation supported by laboratory and imaging studies. Tests may include detection of viral DNA (e.g., CMV in cerebrospinal fluid), serologic testing for Lyme disease, toxin identification in suspected botulism, and cerebrospinal fluid analysis in GBS, which classically shows elevated protein with normal cell count. Imaging such as MRI may demonstrate nerve root enhancement, while nerve conduction studies help assess the extent of nerve involvement.
Management is directed at the underlying cause. Antiviral therapy (e.g., acyclovir for HSV/VZV, ganciclovir for CMV) is used for viral infections, while bacterial causes like Lyme disease are treated with doxycycline or ceftriaxone. Toxin-mediated conditions require antitoxins and supportive care. For GBS, early treatment with plasmapheresis or intravenous immunoglobulin (IVIG) is essential to reduce disease severity and duration. Supportive care, including monitoring for respiratory failure, managing autonomic instability, and rehabilitation, plays a critical role in recovery.
Complications can be significant, particularly in GBS, where patients may experience residual neurologic deficits, recurrence, or prolonged disability. Early recognition and prompt management are crucial to improving outcomes and reducing long-term morbidity.
Infectious neuropathies refer to inflammation or dysfunction of peripheral nerves caused by infectious agents or their toxins, including viruses, bacteria, parasites, and toxin-mediated mechanisms. A key example is Guillain-Barré syndrome (GBS), an immune-mediated neuropathy often triggered by a preceding infection. GBS has an incidence of approximately 1.2–3 cases per 100,000 people and can occur at any age, with peaks in young adults and older individuals. Risk factors vary depending on the cause and include immunosuppression (e.g., HIV/AIDS), advanced age, and exposure to endemic infections such as Lyme disease, leprosy, or Chagas disease. Preventive measures include vaccination (e.g., zoster, rabies, tetanus) and, in specific situations like tick exposure, prophylactic antibiotics.
The pathophysiology differs by condition but often involves either direct infection of nerve tissue or immune-mediated damage. In GBS, a prior infection triggers an immune response that cross-reacts with peripheral nerve components, leading to demyelination (most common) or axonal injury. Infectious causes include viruses such as herpes simplex virus (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), and HIV; bacteria such as Borrelia burgdorferi (Lyme disease) and Mycobacterium leprae (leprosy); parasites like Trypanosoma cruzi; and toxins from organisms such as Clostridium botulinum and Corynebacterium diphtheriae. Additionally, many cases of GBS are preceded by infections like Campylobacter jejuni, respiratory viruses, or gastrointestinal illnesses.
Clinical presentation depends on the underlying cause. Viral neuropathies often present with pain and dermatomal rashes, as seen in herpes zoster, or progressive sensory and motor deficits, as in CMV or HIV-related neuropathies. Bacterial causes such as Lyme disease may produce cranial nerve palsies, meningitis, or radiculopathy, while leprosy leads to sensory loss and nerve thickening. Toxin-mediated neuropathies have distinctive features, such as descending paralysis in botulism or muscle spasms in tetanus. In contrast, GBS typically begins with ascending symmetric weakness starting in the lower limbs, progressing over days to weeks and potentially involving respiratory muscles and autonomic dysfunction.
Diagnosis relies on clinical evaluation supported by laboratory and imaging studies. Tests may include detection of viral DNA (e.g., CMV in cerebrospinal fluid), serologic testing for Lyme disease, toxin identification in suspected botulism, and cerebrospinal fluid analysis in GBS, which classically shows elevated protein with normal cell count. Imaging such as MRI may demonstrate nerve root enhancement, while nerve conduction studies help assess the extent of nerve involvement.
Management is directed at the underlying cause. Antiviral therapy (e.g., acyclovir for HSV/VZV, ganciclovir for CMV) is used for viral infections, while bacterial causes like Lyme disease are treated with doxycycline or ceftriaxone. Toxin-mediated conditions require antitoxins and supportive care. For GBS, early treatment with plasmapheresis or intravenous immunoglobulin (IVIG) is essential to reduce disease severity and duration. Supportive care, including monitoring for respiratory failure, managing autonomic instability, and rehabilitation, plays a critical role in recovery.
Complications can be significant, particularly in GBS, where patients may experience residual neurologic deficits, recurrence, or prolonged disability. Early recognition and prompt management are crucial to improving outcomes and reducing long-term morbidity.
- Published on
Infectious disease and microbiology – Necrotizing soft-tissue infections
Necrotizing soft-tissue infections (NSTIs) are rapidly progressive, life-threatening infections that involve the fascia and may extend to muscles, leading to extensive tissue destruction. They usually arise after a break in the skin, such as trauma, surgery, or even minor events like insect bites, although in many cases no clear initiating factor is identified. Clinically, they may present as necrotizing cellulitis, necrotizing fasciitis, or pyomyositis, and they are associated with high mortality rates exceeding 20%, often reaching around one-third of cases.
The incidence of NSTIs has been increasing, and although still uncommon, most clinicians will encounter at least one case during their practice. Risk factors include immunocompromised states, particularly diabetes mellitus and peripheral vascular disease, as well as obesity, chronic liver or renal disease, HIV infection, intravenous drug use, older age, and frequent hospitalizations. Certain populations, such as athletes or institutionalized individuals, are more prone to infections caused by community-associated MRSA.
Pathophysiologically, bacteria invade subcutaneous tissues and spread rapidly along fascial planes. The production of toxins and enzymes leads to local ischemia, impaired immune response, and widespread necrosis, allowing the infection to advance quickly. Most cases are polymicrobial (Type 1), involving a mixture of aerobic and anaerobic organisms, while others are monomicrobial (Types 2 and 3), commonly caused by Group A Streptococcus, Staphylococcus aureus, or Clostridium species.
Clinically, early symptoms may appear deceptively mild, with pain, erythema, swelling, and tachycardia, but the hallmark is pain out of proportion to physical findings. As the disease progresses, patients develop skin discoloration, bullae, crepitus, anesthesia, and systemic signs such as fever, hypotension, and shock, often rapidly progressing to sepsis and multi-organ failure. Diagnosis is primarily clinical, and urgent surgical exploration remains the gold standard, as delays can be fatal. Laboratory findings and scoring systems such as the LRINEC score may support suspicion, while imaging (CT or MRI) can reveal fascial thickening or gas in tissues but should not delay treatment.
Management requires immediate and aggressive intervention, combining broad-spectrum intravenous antibiotics with early surgical debridement, which is the most critical factor in reducing mortality. Empiric antibiotic therapy should cover gram-positive, gram-negative, and anaerobic organisms, with adjustments based on culture results. Repeated surgical exploration is often necessary, and in severe cases, amputation may be required. Patients typically require intensive care support, including fluid resuscitation, hemodynamic stabilization, and nutritional support.
Despite advances in management, prognosis remains serious. Mortality has improved with early recognition and aggressive treatment but remains high, and survivors often face significant morbidity. Complications include sepsis, acute respiratory distress syndrome, renal failure, nosocomial infections, and limb loss, highlighting the importance of prompt diagnosis and multidisciplinary management.
Necrotizing soft-tissue infections (NSTIs) are rapidly progressive, life-threatening infections that involve the fascia and may extend to muscles, leading to extensive tissue destruction. They usually arise after a break in the skin, such as trauma, surgery, or even minor events like insect bites, although in many cases no clear initiating factor is identified. Clinically, they may present as necrotizing cellulitis, necrotizing fasciitis, or pyomyositis, and they are associated with high mortality rates exceeding 20%, often reaching around one-third of cases.
The incidence of NSTIs has been increasing, and although still uncommon, most clinicians will encounter at least one case during their practice. Risk factors include immunocompromised states, particularly diabetes mellitus and peripheral vascular disease, as well as obesity, chronic liver or renal disease, HIV infection, intravenous drug use, older age, and frequent hospitalizations. Certain populations, such as athletes or institutionalized individuals, are more prone to infections caused by community-associated MRSA.
Pathophysiologically, bacteria invade subcutaneous tissues and spread rapidly along fascial planes. The production of toxins and enzymes leads to local ischemia, impaired immune response, and widespread necrosis, allowing the infection to advance quickly. Most cases are polymicrobial (Type 1), involving a mixture of aerobic and anaerobic organisms, while others are monomicrobial (Types 2 and 3), commonly caused by Group A Streptococcus, Staphylococcus aureus, or Clostridium species.
Clinically, early symptoms may appear deceptively mild, with pain, erythema, swelling, and tachycardia, but the hallmark is pain out of proportion to physical findings. As the disease progresses, patients develop skin discoloration, bullae, crepitus, anesthesia, and systemic signs such as fever, hypotension, and shock, often rapidly progressing to sepsis and multi-organ failure. Diagnosis is primarily clinical, and urgent surgical exploration remains the gold standard, as delays can be fatal. Laboratory findings and scoring systems such as the LRINEC score may support suspicion, while imaging (CT or MRI) can reveal fascial thickening or gas in tissues but should not delay treatment.
Management requires immediate and aggressive intervention, combining broad-spectrum intravenous antibiotics with early surgical debridement, which is the most critical factor in reducing mortality. Empiric antibiotic therapy should cover gram-positive, gram-negative, and anaerobic organisms, with adjustments based on culture results. Repeated surgical exploration is often necessary, and in severe cases, amputation may be required. Patients typically require intensive care support, including fluid resuscitation, hemodynamic stabilization, and nutritional support.
Despite advances in management, prognosis remains serious. Mortality has improved with early recognition and aggressive treatment but remains high, and survivors often face significant morbidity. Complications include sepsis, acute respiratory distress syndrome, renal failure, nosocomial infections, and limb loss, highlighting the importance of prompt diagnosis and multidisciplinary management.
- Published on
Infectious disease and microbiology – Myocarditis
Myocarditis is an inflammatory condition of the heart muscle (myocardium) that can result from a wide range of infectious agents, immune-mediated mechanisms, or external toxins. It may occur due to direct infection of cardiac tissue or from an immune response in which antibodies cross-react with myocardial cells, leading to damage. Although relatively uncommon, with an estimated incidence of 1–10 cases per 100,000 individuals, myocarditis is clinically significant because it contributes to up to 12% of sudden cardiac deaths in adolescents and young adults, affecting young males. Its true prevalence is difficult to determine because presentations range from mild, self-limited illness to severe heart failure or sudden death.
The disease is associated with numerous infectious causes, most commonly viral pathogens such as enteroviruses (especially Coxsackie B), adenovirus, influenza, cytomegalovirus, Epstein-Barr virus, HIV, and others. Bacterial, rickettsial, spirochetal, fungal, protozoal, and parasitic infections may also lead to myocarditis. Notably, Trypanosoma cruzi (Chagas disease) and HIV are important contributors in certain populations. Noninfectious triggers such as toxins, drugs, and systemic inflammatory diseases can also play a role. Immunocompromised individuals are at increased risk, and vaccination against viral pathogens may help reduce incidence.
Pathophysiologically, myocardial injury results from a combination of direct cytotoxic effects of pathogens, immune-mediated inflammation, cytokine release (e.g., tumor necrosis factor-alpha), and apoptosis of cardiac cells, all of which impair cardiac function.
Clinically, patients often report a recent viral-like illness with fever, malaise, or respiratory symptoms, followed by chest pain, palpitations, shortness of breath, or syncope. In some cases, myocarditis mimics acute myocardial infarction, while in others it presents later as chronic heart failure. Physical examination may reveal tachycardia, arrhythmias, signs of heart failure, or an S3 gallop, along with systemic features depending on the underlying cause.
Diagnosis involves a combination of laboratory testing, imaging, and sometimes biopsy. Laboratory findings may include leukocytosis, elevated inflammatory markers, and increased cardiac enzymes such as troponin. Imaging studies—especially echocardiography and cardiac MRI—help assess cardiac function and inflammation. Electrocardiography often shows nonspecific changes or conduction abnormalities. The gold standard for diagnosis is endomyocardial biopsy, which demonstrates inflammatory infiltration and myocardial necrosis, although it carries procedural risks and may yield false negatives.
Management is largely supportive, focusing on treatment of heart failure with medications such as diuretics, ACE inhibitors, and beta-blockers. Specific antimicrobial or antiviral therapy is used when an identifiable cause is present. In severe cases, advanced supportive measures such as ventricular assist devices or extracorporeal membrane oxygenation may be required, and cardiac transplantation may be considered in refractory cases. Adjunctive therapies such as intravenous immunoglobulin or immunosuppressive agents may be used selectively.
Follow-up care includes gradual rehabilitation, serial cardiac monitoring, and repeat imaging, with restrictions on physical activity during recovery. Long-term outcomes vary: some patients recover completely, while others develop complications such as dilated cardiomyopathy, arrhythmias, heart block, or cardiogenic shock. Early recognition and appropriate management are essential to improve prognosis and reduce the risk of serious complications, including sudden cardiac death.
Myocarditis is an inflammatory condition of the heart muscle (myocardium) that can result from a wide range of infectious agents, immune-mediated mechanisms, or external toxins. It may occur due to direct infection of cardiac tissue or from an immune response in which antibodies cross-react with myocardial cells, leading to damage. Although relatively uncommon, with an estimated incidence of 1–10 cases per 100,000 individuals, myocarditis is clinically significant because it contributes to up to 12% of sudden cardiac deaths in adolescents and young adults, affecting young males. Its true prevalence is difficult to determine because presentations range from mild, self-limited illness to severe heart failure or sudden death.
The disease is associated with numerous infectious causes, most commonly viral pathogens such as enteroviruses (especially Coxsackie B), adenovirus, influenza, cytomegalovirus, Epstein-Barr virus, HIV, and others. Bacterial, rickettsial, spirochetal, fungal, protozoal, and parasitic infections may also lead to myocarditis. Notably, Trypanosoma cruzi (Chagas disease) and HIV are important contributors in certain populations. Noninfectious triggers such as toxins, drugs, and systemic inflammatory diseases can also play a role. Immunocompromised individuals are at increased risk, and vaccination against viral pathogens may help reduce incidence.
Pathophysiologically, myocardial injury results from a combination of direct cytotoxic effects of pathogens, immune-mediated inflammation, cytokine release (e.g., tumor necrosis factor-alpha), and apoptosis of cardiac cells, all of which impair cardiac function.
Clinically, patients often report a recent viral-like illness with fever, malaise, or respiratory symptoms, followed by chest pain, palpitations, shortness of breath, or syncope. In some cases, myocarditis mimics acute myocardial infarction, while in others it presents later as chronic heart failure. Physical examination may reveal tachycardia, arrhythmias, signs of heart failure, or an S3 gallop, along with systemic features depending on the underlying cause.
Diagnosis involves a combination of laboratory testing, imaging, and sometimes biopsy. Laboratory findings may include leukocytosis, elevated inflammatory markers, and increased cardiac enzymes such as troponin. Imaging studies—especially echocardiography and cardiac MRI—help assess cardiac function and inflammation. Electrocardiography often shows nonspecific changes or conduction abnormalities. The gold standard for diagnosis is endomyocardial biopsy, which demonstrates inflammatory infiltration and myocardial necrosis, although it carries procedural risks and may yield false negatives.
Management is largely supportive, focusing on treatment of heart failure with medications such as diuretics, ACE inhibitors, and beta-blockers. Specific antimicrobial or antiviral therapy is used when an identifiable cause is present. In severe cases, advanced supportive measures such as ventricular assist devices or extracorporeal membrane oxygenation may be required, and cardiac transplantation may be considered in refractory cases. Adjunctive therapies such as intravenous immunoglobulin or immunosuppressive agents may be used selectively.
Follow-up care includes gradual rehabilitation, serial cardiac monitoring, and repeat imaging, with restrictions on physical activity during recovery. Long-term outcomes vary: some patients recover completely, while others develop complications such as dilated cardiomyopathy, arrhythmias, heart block, or cardiogenic shock. Early recognition and appropriate management are essential to improve prognosis and reduce the risk of serious complications, including sudden cardiac death.
- Published on
Infectious disease and microbiology – Myelitis
Myelitis is an inflammatory condition of the spinal cord caused by infection or involvement of adjacent tissues, leading to neurologic dysfunction affecting motor, sensory, and autonomic systems.
The epidemiology varies widely depending on the underlying infectious cause. It can occur in both immunocompetent and immunocompromised individuals, although the latter are at higher risk.
Risk Factors
Inflammation may involve:
Etiology
A wide range of infectious agents can cause myelitis:
Viral causes (most common):
History:
Transverse Myelitis:
Laboratory Tests:
Noninfectious causes include:
Targeted antimicrobial therapy based on cause:
Myelitis is an inflammatory condition of the spinal cord caused by infection or involvement of adjacent tissues, leading to neurologic dysfunction affecting motor, sensory, and autonomic systems.
The epidemiology varies widely depending on the underlying infectious cause. It can occur in both immunocompetent and immunocompromised individuals, although the latter are at higher risk.
Risk Factors
- Immunocompromised state (e.g., HIV, malignancy, steroid use)
- Vaccination against poliomyelitis and varicella-zoster virus (VZV)
Inflammation may involve:
- Entire cross-section of the spinal cord → transverse myelitis
- Focal segments → localized myelitis
- Nerve roots involvement → radiculomyelitis
Etiology
A wide range of infectious agents can cause myelitis:
Viral causes (most common):
- Herpes viruses (HSV, EBV, VZV, CMV, HHV-6)
- HIV (vacuolar myelopathy)
- HTLV-1 (tropical spastic paraparesis)
- Influenza virus
- Enteroviruses (coxsackie, echovirus, enterovirus 70/71)
- West Nile virus
- Mycoplasma pneumoniae
- Lyme disease (Borrelia burgdorferi)
- Syphilis (posterior column involvement – tabes dorsalis)
- Tuberculosis (spondylitis, tuberculomas)
- Leptospirosis
- Aspergillus, Coccidioides, Blastomyces
- Schistosomiasis
- Neurocysticercosis
- Epidural abscess causing spinal cord compression
History:
- Rapid onset (hours to days)
- Motor weakness (often bilateral)
- Sensory disturbances
- Bladder and bowel dysfunction
- Back pain or radicular (dermatomal) pain
Transverse Myelitis:
- Sensory level on the trunk
- Loss of motor and sensory function below lesion
- Reflexes initially decreased, later hyperactive
- Asymmetric weakness
- Fasciculations and muscle atrophy
- Loss of reflexes (lower motor neuron signs)
- Dermatomal pain and sensory loss
- Ipsilateral to rash
- Motor involvement is less common
Laboratory Tests:
- CSF analysis:
- Cell count, glucose, protein
- PCR for HSV, CMV, VZV
- West Nile virus IgM
- VDRL (for syphilis)
- Serology for HIV, Lyme disease, enteroviruses
- Normal glucose (viral causes)
- Elevated protein
- Lymphocytic predominance (except early herpes infections)
- MRI of the spine shows focal or diffuse enhancing lesions
- Inflammatory infiltration (lymphocytes, monocytes)
- Demyelination and axonal injury
Noninfectious causes include:
- Multiple sclerosis
- Vitamin B12 deficiency
- Autoimmune diseases (e.g., SLE)
- Neurosarcoidosis
- Paraneoplastic syndromes
Targeted antimicrobial therapy based on cause:
- HSV → Acyclovir
- CMV → Ganciclovir or foscarnet
- HIV → Antiretroviral therapy
- Other infections → Etiology-specific treatment
- Corticosteroids (e.g., IV methylprednisolone) are often used, though their benefit remains uncertain
- Emergency decompression if spinal cord compression (e.g., epidural abscess) is present
- Patients often require rehabilitation and neurologic follow-up
- Relapses may occur depending on etiology
- Chronic neuropathic pain
- Partial or complete paralysis
- Published on
Infectious disease and microbiology – Myositis
Myositis is an inflammatory condition of skeletal muscles that may arise from infectious causes—including bacteria, viruses, fungi, parasites, and mycobacteria—or from noninfectious conditions. A specific form, pyomyositis, refers to a hematogenous bacterial infection of muscle that frequently leads to abscess formation, whereas acute bacterial myositis involves diffuse muscle infection without abscess. The epidemiology varies depending on the causative organism, but pyomyositis is relatively rare in temperate regions and more common in tropical areas, where it may account for a notable proportion of hospital admissions. Risk factors include immunocompromised states such as HIV infection, chronic illnesses like diabetes and malignancy, alcoholism, trauma, surgery, obesity, and residence in tropical climates.
The pathophysiology often involves muscle injury or trauma, which may create a susceptible environment for infection due to local infarction or hemorrhage. A wide range of pathogens can cause myositis: viral agents such as influenza, HIV, and herpes viruses; parasitic organisms like Trichinella spiralis, Toxoplasma gondii, and Echinococcus; and bacterial pathogens, most notably Staphylococcus aureus, which accounts for the majority of pyomyositis cases. Other bacterial causes include streptococci, clostridia (leading to gas gangrene), and mixed aerobic and anaerobic organisms. Fungal infections and infections related to aquatic exposure (e.g., Aeromonas hydrophila, Vibrio vulnificus) are less common but clinically important.
Clinically, myositis often presents insidiously with localized muscle pain and fever, progressing to swelling, induration, and marked tenderness. Deep muscle infections may lack overlying skin changes, making diagnosis challenging. In advanced cases, findings such as crepitus, malodorous discharge, hemorrhagic bullae, or systemic signs of sepsis may appear. Laboratory evaluation typically shows leukocytosis and elevated muscle enzymes, while cultures from deep tissue or aspirated material are essential for identifying the causative organism. Imaging studies such as CT or MRI help determine the extent of muscle involvement and detect abscess formation, while ultrasound can assist in emergency settings.
Management usually requires a combined medical and surgical approach, particularly for bacterial myositis. Abscesses should be drained, and empiric antibiotic therapy should cover common pathogens such as S. aureus, with adjustments based on culture results. Severe infections, such as those caused by streptococci or clostridia, require urgent surgical debridement and high-dose antibiotics, often including penicillin and clindamycin. Treatment of parasitic infections depends on the specific organism, while viral myositis is generally managed supportively. Additional therapies, such as hyperbaric oxygen for clostridial infections or immunoglobulin in toxic shock, may be indicated in selected cases.
Patients often require hospitalization, especially in bacterial or severe parasitic cases, with close monitoring and supportive care. Despite treatment, prognosis can be serious in severe infections, particularly those caused by streptococci or clostridia, which carry high mortality rates. Potential complications include bacteremia, septic shock, limb necrosis, toxic shock syndrome, and death, underscoring the importance of early recognition and aggressive management.
Myositis is an inflammatory condition of skeletal muscles that may arise from infectious causes—including bacteria, viruses, fungi, parasites, and mycobacteria—or from noninfectious conditions. A specific form, pyomyositis, refers to a hematogenous bacterial infection of muscle that frequently leads to abscess formation, whereas acute bacterial myositis involves diffuse muscle infection without abscess. The epidemiology varies depending on the causative organism, but pyomyositis is relatively rare in temperate regions and more common in tropical areas, where it may account for a notable proportion of hospital admissions. Risk factors include immunocompromised states such as HIV infection, chronic illnesses like diabetes and malignancy, alcoholism, trauma, surgery, obesity, and residence in tropical climates.
The pathophysiology often involves muscle injury or trauma, which may create a susceptible environment for infection due to local infarction or hemorrhage. A wide range of pathogens can cause myositis: viral agents such as influenza, HIV, and herpes viruses; parasitic organisms like Trichinella spiralis, Toxoplasma gondii, and Echinococcus; and bacterial pathogens, most notably Staphylococcus aureus, which accounts for the majority of pyomyositis cases. Other bacterial causes include streptococci, clostridia (leading to gas gangrene), and mixed aerobic and anaerobic organisms. Fungal infections and infections related to aquatic exposure (e.g., Aeromonas hydrophila, Vibrio vulnificus) are less common but clinically important.
Clinically, myositis often presents insidiously with localized muscle pain and fever, progressing to swelling, induration, and marked tenderness. Deep muscle infections may lack overlying skin changes, making diagnosis challenging. In advanced cases, findings such as crepitus, malodorous discharge, hemorrhagic bullae, or systemic signs of sepsis may appear. Laboratory evaluation typically shows leukocytosis and elevated muscle enzymes, while cultures from deep tissue or aspirated material are essential for identifying the causative organism. Imaging studies such as CT or MRI help determine the extent of muscle involvement and detect abscess formation, while ultrasound can assist in emergency settings.
Management usually requires a combined medical and surgical approach, particularly for bacterial myositis. Abscesses should be drained, and empiric antibiotic therapy should cover common pathogens such as S. aureus, with adjustments based on culture results. Severe infections, such as those caused by streptococci or clostridia, require urgent surgical debridement and high-dose antibiotics, often including penicillin and clindamycin. Treatment of parasitic infections depends on the specific organism, while viral myositis is generally managed supportively. Additional therapies, such as hyperbaric oxygen for clostridial infections or immunoglobulin in toxic shock, may be indicated in selected cases.
Patients often require hospitalization, especially in bacterial or severe parasitic cases, with close monitoring and supportive care. Despite treatment, prognosis can be serious in severe infections, particularly those caused by streptococci or clostridia, which carry high mortality rates. Potential complications include bacteremia, septic shock, limb necrosis, toxic shock syndrome, and death, underscoring the importance of early recognition and aggressive management.
- Published on
Infectious Disease and Microbiology - Mastoiditis
Mastoiditis is an infection and inflammation of the mastoid air cells of the temporal bone, typically classified as acute or chronic based on duration. Acute mastoiditis usually follows untreated or inadequately treated middle ear infection, whereas chronic mastoiditis is characterized by persistent ear discharge lasting more than three weeks, often associated with a perforated tympanic membrane.
The incidence of mastoiditis has significantly declined in the antibiotic era due to prompt treatment of otitis media. However, a recent shift toward conservative management of ear infections has led to a slight increase in cases in some regions. It remains a relatively rare condition, with incidence rates ranging from approximately 1.2 to 3.8 cases per 100,000 patient-years. Risk factors include inadequate treatment of otitis media, lack of vaccination against Streptococcus pneumoniae and Haemophilus influenzae, and the presence of cochlear implants.
The disease typically develops as an extension of infection from the middle ear into the mastoid air cells. In acute mastoiditis, the most common causative organisms mirror those of acute otitis media, including Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, and Pseudomonas aeruginosa. Chronic mastoiditis is often polymicrobial, involving organisms such as Pseudomonas aeruginosa, Staphylococcus aureus, gram-negative bacilli, anaerobes, and rarely fungi or mycobacteria.
Clinically, patients often present with symptoms of acute otitis media, including fever, ear pain, and hearing impairment. Physical examination reveals erythema of the tympanic membrane, ear discharge (otorrhea), and characteristic postauricular findings such as swelling, tenderness, and redness over the mastoid region. A key sign is displacement of the pinna outward and downward. In chronic cases, symptoms may be more subtle, including persistent ear discharge and hearing loss.
Diagnosis is supported by laboratory findings such as elevated white blood cell count and inflammatory markers (CRP and ESR). Imaging plays a crucial role, with radiographs showing destruction of mastoid air cell septa and fluid accumulation, while CT or MRI provides detailed assessment of disease extent and complications. Microbiological diagnosis is achieved through culture of ear discharge or middle ear fluid obtained via tympanocentesis.
Management requires prompt and aggressive treatment due to the risk of serious complications. Intravenous antibiotics are the mainstay of therapy, typically using broad-spectrum agents such as third- or fourth-generation cephalosporins, piperacillin-tazobactam, or combinations targeting resistant organisms. Treatment duration is usually 3–4 weeks, with transition to oral therapy after clinical improvement. Chronic mastoiditis may also require local antibiotic therapy and meticulous ear care.
Surgical intervention is indicated in cases of treatment failure, complications, or evidence of bone destruction. Procedures such as mastoidectomy are performed to remove infected tissue and prevent further spread. Less invasive approaches, including drainage and ventilation tube placement, may be considered in selected cases without intracranial involvement.
The prognosis is generally very good when mastoiditis is diagnosed early and treated appropriately. However, delayed or inadequate treatment can lead to serious complications, including subperiosteal abscess, facial nerve paralysis, intracranial infections such as meningitis or brain abscess, and permanent hearing loss.
- Published on
1. Infectious Disease and Microbiology - Malaria
Malaria is a vector-borne parasitic disease transmitted by the bite of an infected female Anopheles mosquito. It is caused by protozoa of the genus Plasmodium and remains one of the most significant global infectious diseases, particularly affecting tropical and subtropical regions. The infection begins when sporozoites are introduced into the bloodstream, subsequently invading liver cells and later red blood cells, leading to systemic illness.
Malaria has a massive global burden, with hundreds of millions of cases annually and millions of deaths, most of which occur in children. It affects over 40% of the world’s population across more than 100 countries. Different species have distinct geographic distributions: Plasmodium falciparum predominates in Africa and is responsible for the most severe disease, while P. vivax, P. ovale, and P. malariae are distributed across other regions. Risk factors include travel to endemic areas, lack of immunity, and, rarely, transmission through blood transfusion or from mother to fetus. Certain genetic traits, such as sickle cell trait, offer partial protection against severe disease.
The pathophysiology involves a complex life cycle between the mosquito and human host. After liver-stage development, parasites invade red blood cells, multiply, and cause their destruction. This leads to hemolysis, release of inflammatory cytokines, and the characteristic febrile illness. P. falciparum is particularly dangerous due to its ability to cause cytoadherence, leading to sequestration of infected red blood cells in small blood vessels, resulting in impaired blood flow and organ dysfunction.
Clinically, malaria presents with nonspecific symptoms such as fever, malaise, headache, and myalgias. A hallmark feature is the malarial paroxysm, consisting of a cold stage with chills, a hot stage with high fever (often exceeding 40°C), and a sweating stage with resolution of fever and profound fatigue. Splenomegaly and tachycardia are common findings. Although fever patterns may be cyclic (tertian or quartan), this periodicity is not always reliable for diagnosis.
Diagnosis is primarily established by microscopic examination of thick and thin blood smears, which allows detection and identification of the parasite species. Rapid diagnostic tests detecting specific antigens are also widely used, especially in resource-limited settings. Laboratory findings often include anemia, thrombocytopenia, and markers of hemolysis. Molecular methods such as PCR can provide confirmation but are not routinely available.
Treatment depends on the species, severity, and drug resistance patterns. Uncomplicated malaria caused by chloroquine-sensitive strains can be treated with chloroquine, while resistant infections require agents such as atovaquone-proguanil, artemisinin-based combinations, or quinine-based regimens. Severe malaria, particularly due to P. falciparum, is a medical emergency requiring intravenous therapy such as artesunate or quinidine, along with intensive supportive care. Monitoring for complications such as hypoglycemia and renal failure is essential.
Preventive strategies focus on reducing mosquito exposure and chemoprophylaxis. Measures include insecticide-treated bed nets, protective clothing, and repellents such as DEET. Travelers to endemic regions may require prophylactic medications depending on resistance patterns. Individuals returning to endemic areas after prolonged absence are at increased risk due to loss of immunity.
The prognosis of malaria depends on early diagnosis and appropriate treatment. Uncomplicated malaria generally responds well to therapy, while untreated P. falciparum infection can lead to severe complications such as cerebral malaria, renal failure, metabolic acidosis, and death. Prompt recognition and management are critical to reducing morbidity and mortality.
Malaria is a vector-borne parasitic disease transmitted by the bite of an infected female Anopheles mosquito. It is caused by protozoa of the genus Plasmodium and remains one of the most significant global infectious diseases, particularly affecting tropical and subtropical regions. The infection begins when sporozoites are introduced into the bloodstream, subsequently invading liver cells and later red blood cells, leading to systemic illness.
Malaria has a massive global burden, with hundreds of millions of cases annually and millions of deaths, most of which occur in children. It affects over 40% of the world’s population across more than 100 countries. Different species have distinct geographic distributions: Plasmodium falciparum predominates in Africa and is responsible for the most severe disease, while P. vivax, P. ovale, and P. malariae are distributed across other regions. Risk factors include travel to endemic areas, lack of immunity, and, rarely, transmission through blood transfusion or from mother to fetus. Certain genetic traits, such as sickle cell trait, offer partial protection against severe disease.
The pathophysiology involves a complex life cycle between the mosquito and human host. After liver-stage development, parasites invade red blood cells, multiply, and cause their destruction. This leads to hemolysis, release of inflammatory cytokines, and the characteristic febrile illness. P. falciparum is particularly dangerous due to its ability to cause cytoadherence, leading to sequestration of infected red blood cells in small blood vessels, resulting in impaired blood flow and organ dysfunction.
Clinically, malaria presents with nonspecific symptoms such as fever, malaise, headache, and myalgias. A hallmark feature is the malarial paroxysm, consisting of a cold stage with chills, a hot stage with high fever (often exceeding 40°C), and a sweating stage with resolution of fever and profound fatigue. Splenomegaly and tachycardia are common findings. Although fever patterns may be cyclic (tertian or quartan), this periodicity is not always reliable for diagnosis.
Diagnosis is primarily established by microscopic examination of thick and thin blood smears, which allows detection and identification of the parasite species. Rapid diagnostic tests detecting specific antigens are also widely used, especially in resource-limited settings. Laboratory findings often include anemia, thrombocytopenia, and markers of hemolysis. Molecular methods such as PCR can provide confirmation but are not routinely available.
Treatment depends on the species, severity, and drug resistance patterns. Uncomplicated malaria caused by chloroquine-sensitive strains can be treated with chloroquine, while resistant infections require agents such as atovaquone-proguanil, artemisinin-based combinations, or quinine-based regimens. Severe malaria, particularly due to P. falciparum, is a medical emergency requiring intravenous therapy such as artesunate or quinidine, along with intensive supportive care. Monitoring for complications such as hypoglycemia and renal failure is essential.
Preventive strategies focus on reducing mosquito exposure and chemoprophylaxis. Measures include insecticide-treated bed nets, protective clothing, and repellents such as DEET. Travelers to endemic regions may require prophylactic medications depending on resistance patterns. Individuals returning to endemic areas after prolonged absence are at increased risk due to loss of immunity.
The prognosis of malaria depends on early diagnosis and appropriate treatment. Uncomplicated malaria generally responds well to therapy, while untreated P. falciparum infection can lead to severe complications such as cerebral malaria, renal failure, metabolic acidosis, and death. Prompt recognition and management are critical to reducing morbidity and mortality.
- Published on
Infectious Disease and Microbiology - Measles
Measles is a highly contagious viral disease characterized by fever and a distinctive maculopapular rash that begins on the face and spreads downward to the trunk and extremities. The rash is typically preceded by a prodromal phase of cough, coryza, and conjunctivitis, along with the pathognomonic Koplik’s spots on the buccal mucosa. While often self-limited in healthy children, measles remains a major cause of morbidity and mortality, particularly in malnourished or immunocompromised populations.
Globally, measles continues to affect millions of individuals each year, with significant mortality despite widespread vaccination efforts. Although vaccination coverage has improved, outbreaks still occur, especially in low-income countries and in areas affected by conflict or poor healthcare access. Individuals at highest risk include those who are unvaccinated, immunocompromised, pregnant, malnourished, or at extremes of age. Healthcare workers without immunity are also at risk and may contribute to transmission.
The virus spreads via respiratory droplets and initially infects the respiratory mucosa before disseminating through lymphatic and hematogenous routes. It affects multiple organ systems including the skin, conjunctiva, lungs, and gastrointestinal tract. The appearance of the rash corresponds with the host immune response and marks the decline in viral transmissibility. The causative agent is the measles (rubeola) virus, an RNA virus of the Paramyxoviridae family.
Clinically, measles begins with a prodrome of high fever, cough, conjunctivitis, and coryza. Koplik’s spots—small white lesions on the buccal mucosa—appear early and are highly characteristic. This is followed by a red maculopapular rash that starts behind the ears and on the forehead, then spreads downward. The rash typically lasts about five days before fading, sometimes followed by desquamation. In partially immune individuals, atypical and milder presentations may occur.
Diagnosis is primarily clinical, based on characteristic signs and symptoms. Laboratory findings may include leukopenia, T-cell cytopenia, and thrombocytopenia. Serologic testing can confirm diagnosis in atypical cases. Chest imaging may reveal interstitial pneumonitis in severe disease. Viral detection can be performed using immunofluorescence or PCR from respiratory secretions or urine, though this is not always necessary in typical cases.
There is no specific antiviral therapy for measles. Management is mainly supportive, focusing on hydration, fever control, and monitoring for complications. The World Health Organization recommends vitamin A supplementation in children, particularly in developing countries, as it reduces morbidity and mortality. Ribavirin may be considered in severe cases among immunocompromised patients. Antibiotics are reserved only for secondary bacterial infections. Post-exposure prophylaxis with immune serum globulin may prevent or attenuate disease in high-risk individuals.
Prevention is primarily achieved through vaccination with the measles-containing vaccine (commonly the MMR vaccine). The standard schedule includes an initial dose at 12–15 months and a booster at 4–6 years. Vaccination has dramatically reduced global incidence, and there is no evidence linking the vaccine to autism. Certain groups, such as pregnant women and severely immunocompromised individuals, should not receive the live vaccine.
The prognosis is generally excellent in healthy individuals, with lifelong immunity following recovery. However, complications are common in vulnerable populations and may include pneumonia, encephalitis, otitis media, severe diarrhea, and blindness. A rare but fatal long-term complication is subacute sclerosing panencephalitis (SSPE), which can occur years after the initial infection.
Measles is a highly contagious viral disease characterized by fever and a distinctive maculopapular rash that begins on the face and spreads downward to the trunk and extremities. The rash is typically preceded by a prodromal phase of cough, coryza, and conjunctivitis, along with the pathognomonic Koplik’s spots on the buccal mucosa. While often self-limited in healthy children, measles remains a major cause of morbidity and mortality, particularly in malnourished or immunocompromised populations.
Globally, measles continues to affect millions of individuals each year, with significant mortality despite widespread vaccination efforts. Although vaccination coverage has improved, outbreaks still occur, especially in low-income countries and in areas affected by conflict or poor healthcare access. Individuals at highest risk include those who are unvaccinated, immunocompromised, pregnant, malnourished, or at extremes of age. Healthcare workers without immunity are also at risk and may contribute to transmission.
The virus spreads via respiratory droplets and initially infects the respiratory mucosa before disseminating through lymphatic and hematogenous routes. It affects multiple organ systems including the skin, conjunctiva, lungs, and gastrointestinal tract. The appearance of the rash corresponds with the host immune response and marks the decline in viral transmissibility. The causative agent is the measles (rubeola) virus, an RNA virus of the Paramyxoviridae family.
Clinically, measles begins with a prodrome of high fever, cough, conjunctivitis, and coryza. Koplik’s spots—small white lesions on the buccal mucosa—appear early and are highly characteristic. This is followed by a red maculopapular rash that starts behind the ears and on the forehead, then spreads downward. The rash typically lasts about five days before fading, sometimes followed by desquamation. In partially immune individuals, atypical and milder presentations may occur.
Diagnosis is primarily clinical, based on characteristic signs and symptoms. Laboratory findings may include leukopenia, T-cell cytopenia, and thrombocytopenia. Serologic testing can confirm diagnosis in atypical cases. Chest imaging may reveal interstitial pneumonitis in severe disease. Viral detection can be performed using immunofluorescence or PCR from respiratory secretions or urine, though this is not always necessary in typical cases.
There is no specific antiviral therapy for measles. Management is mainly supportive, focusing on hydration, fever control, and monitoring for complications. The World Health Organization recommends vitamin A supplementation in children, particularly in developing countries, as it reduces morbidity and mortality. Ribavirin may be considered in severe cases among immunocompromised patients. Antibiotics are reserved only for secondary bacterial infections. Post-exposure prophylaxis with immune serum globulin may prevent or attenuate disease in high-risk individuals.
Prevention is primarily achieved through vaccination with the measles-containing vaccine (commonly the MMR vaccine). The standard schedule includes an initial dose at 12–15 months and a booster at 4–6 years. Vaccination has dramatically reduced global incidence, and there is no evidence linking the vaccine to autism. Certain groups, such as pregnant women and severely immunocompromised individuals, should not receive the live vaccine.
The prognosis is generally excellent in healthy individuals, with lifelong immunity following recovery. However, complications are common in vulnerable populations and may include pneumonia, encephalitis, otitis media, severe diarrhea, and blindness. A rare but fatal long-term complication is subacute sclerosing panencephalitis (SSPE), which can occur years after the initial infection.
- Published on
Infectious Disease and Microbiology - Lice
Lice infestation, also known as pediculosis, is caused by ectoparasitic insects of the order Phthiraptera that live on human hair and skin. It is not an infection but an infestation, involving three main types depending on location: head lice, body lice, and pubic lice. The causative organisms include Pediculus humanus capitis, Pediculus humanus corporis, and Phthirus pubis. These parasites feed on human blood and complete their life cycle entirely on the host, with eggs (nits) hatching into nymphs that mature into adults within a few weeks.
Head lice infestation is particularly common among school-aged children and spreads mainly through close personal contact. It is not strongly linked to poor hygiene but is associated with crowding and household size. Body lice are more commonly seen in individuals with poor hygiene, especially among homeless populations or in crowded environments such as refugee camps. Pubic lice are typically transmitted through sexual contact and are therefore considered a sexually transmitted condition, often associated with other sexually transmitted infections.
The main symptom of lice infestation is pruritus, which results from a hypersensitivity reaction to lice saliva. The itching varies depending on the site of infestation and may lead to excoriations and secondary bacterial infections. Physical examination is diagnostic, revealing live lice or nits attached to hair shafts or clothing fibers. In head lice, careful combing of wet hair can improve detection. Pubic lice may also affect other coarse hair regions, including eyelashes, and characteristic bluish-gray skin lesions known as maculae ceruleae may appear.
Diagnosis is clinical and does not require laboratory testing. However, in cases of pubic lice, evaluation for coexisting sexually transmitted diseases is recommended. Body lice infestations may be associated with transmission of certain pathogens, including Bartonella quintana and, less commonly, Rickettsia prowazekii, making recognition important in vulnerable populations.
Treatment primarily involves topical insecticides, with permethrin 1% being the first-line therapy for most infestations. Reapplication after 7 to 10 days is often necessary to eradicate newly hatched lice. Alternative treatments include malathion, lindane (with caution due to potential toxicity), and oral ivermectin in selected cases. Proper application technique is essential for treatment success, as resistance or improper use may lead to persistence of infestation.
Supportive measures include washing clothing, bedding, and personal items in hot water, particularly for body lice. For pubic lice affecting the eyelashes, petroleum jelly may be used. Mechanical removal of lice and nits can be helpful but is generally less effective when used alone. The prognosis is excellent with appropriate treatment, although reinfestation can occur if contacts are not treated simultaneously.
Complications are usually mild and include secondary bacterial skin infections due to scratching. In certain cases, particularly with body lice, there is a risk of transmission of systemic infections. Psychological distress, especially among children and caregivers, is also a notable consequence of infestation.
Lice infestation, also known as pediculosis, is caused by ectoparasitic insects of the order Phthiraptera that live on human hair and skin. It is not an infection but an infestation, involving three main types depending on location: head lice, body lice, and pubic lice. The causative organisms include Pediculus humanus capitis, Pediculus humanus corporis, and Phthirus pubis. These parasites feed on human blood and complete their life cycle entirely on the host, with eggs (nits) hatching into nymphs that mature into adults within a few weeks.
Head lice infestation is particularly common among school-aged children and spreads mainly through close personal contact. It is not strongly linked to poor hygiene but is associated with crowding and household size. Body lice are more commonly seen in individuals with poor hygiene, especially among homeless populations or in crowded environments such as refugee camps. Pubic lice are typically transmitted through sexual contact and are therefore considered a sexually transmitted condition, often associated with other sexually transmitted infections.
The main symptom of lice infestation is pruritus, which results from a hypersensitivity reaction to lice saliva. The itching varies depending on the site of infestation and may lead to excoriations and secondary bacterial infections. Physical examination is diagnostic, revealing live lice or nits attached to hair shafts or clothing fibers. In head lice, careful combing of wet hair can improve detection. Pubic lice may also affect other coarse hair regions, including eyelashes, and characteristic bluish-gray skin lesions known as maculae ceruleae may appear.
Diagnosis is clinical and does not require laboratory testing. However, in cases of pubic lice, evaluation for coexisting sexually transmitted diseases is recommended. Body lice infestations may be associated with transmission of certain pathogens, including Bartonella quintana and, less commonly, Rickettsia prowazekii, making recognition important in vulnerable populations.
Treatment primarily involves topical insecticides, with permethrin 1% being the first-line therapy for most infestations. Reapplication after 7 to 10 days is often necessary to eradicate newly hatched lice. Alternative treatments include malathion, lindane (with caution due to potential toxicity), and oral ivermectin in selected cases. Proper application technique is essential for treatment success, as resistance or improper use may lead to persistence of infestation.
Supportive measures include washing clothing, bedding, and personal items in hot water, particularly for body lice. For pubic lice affecting the eyelashes, petroleum jelly may be used. Mechanical removal of lice and nits can be helpful but is generally less effective when used alone. The prognosis is excellent with appropriate treatment, although reinfestation can occur if contacts are not treated simultaneously.
Complications are usually mild and include secondary bacterial skin infections due to scratching. In certain cases, particularly with body lice, there is a risk of transmission of systemic infections. Psychological distress, especially among children and caregivers, is also a notable consequence of infestation.
- Published on
Infectious Disease and Microbiology - Lung abscess
A lung abscess is a localized collection of pus within the lung parenchyma, resulting in a cavity formed by necrosis of lung tissue due to microbial infection. It may present as a single large cavity or as multiple smaller abscesses, the latter often referred to as necrotizing pneumonia. Lung abscesses can be classified as primary, occurring in otherwise healthy individuals, or secondary, associated with underlying conditions such as malignancy, bronchiectasis, or immunosuppression. Although more common in the pre-antibiotic era, lung abscesses are now relatively uncommon but remain clinically significant due to potential complications.
The most important risk factor is aspiration of oropharyngeal contents, particularly in individuals with impaired consciousness, dysphagia, or poor dental hygiene. Conditions such as alcoholism, general anesthesia, seizures, and gastroesophageal reflux disease increase the risk of aspiration. Periodontal disease plays a major role by providing a source of anaerobic bacteria. Other risk factors include airway obstruction, immunocompromised states such as HIV or diabetes, and hematogenous spread from infections like right-sided endocarditis.
Pathophysiologically, microorganisms—most commonly anaerobic bacteria—enter the lung through aspiration and proliferate in areas with poor clearance. This leads to tissue necrosis and cavity formation. Less commonly, abscesses arise from septic emboli traveling through the bloodstream. The most frequent causative organisms include anaerobes such as Peptostreptococcus, Fusobacterium, Prevotella, and Bacteroides species, often in combination with aerobic bacteria. Aerobic pathogens include Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa, with resistant organisms such as MRSA being increasingly recognized.
Clinically, patients typically present with cough producing foul-smelling, purulent sputum, fever, and pleuritic chest pain. In chronic cases, symptoms may persist for weeks and include weight loss, fatigue, night sweats, and malaise. Physical examination may reveal tachycardia, tachypnea, and abnormal lung findings such as crackles, decreased breath sounds, or signs of consolidation. Digital clubbing may develop in longstanding disease.
Diagnosis involves laboratory and imaging studies. Blood tests often show leukocytosis, while sputum cultures may be inconclusive, especially for anaerobic infections. Chest imaging is essential, with radiographs typically showing a cavity with an air–fluid level. CT scanning provides better anatomical detail and helps identify underlying causes such as obstruction or malignancy. Additional procedures such as bronchoscopy or needle aspiration may be required in atypical or nonresponsive cases.
Treatment consists primarily of prolonged antibiotic therapy targeting both anaerobic and aerobic organisms. First-line regimens include clindamycin or beta-lactam/beta-lactamase inhibitor combinations such as ampicillin-sulbactam, followed by oral therapy once clinical improvement occurs. The duration of therapy may extend from several weeks to months, depending on radiologic resolution. Supportive measures such as postural drainage and pulmonary physiotherapy are important adjuncts. In cases unresponsive to medical therapy, percutaneous or surgical drainage may be necessary.
The prognosis is generally good with appropriate treatment, although mortality ranges from 5% to 15%. Poor prognostic factors include large cavity size, delayed diagnosis, underlying comorbidities, and infection with resistant organisms. Complications may include empyema, massive hemoptysis, pneumothorax, and dissemination leading to conditions such as brain abscess. Careful follow-up with serial imaging is required to ensure resolution of the infection.
A lung abscess is a localized collection of pus within the lung parenchyma, resulting in a cavity formed by necrosis of lung tissue due to microbial infection. It may present as a single large cavity or as multiple smaller abscesses, the latter often referred to as necrotizing pneumonia. Lung abscesses can be classified as primary, occurring in otherwise healthy individuals, or secondary, associated with underlying conditions such as malignancy, bronchiectasis, or immunosuppression. Although more common in the pre-antibiotic era, lung abscesses are now relatively uncommon but remain clinically significant due to potential complications.
The most important risk factor is aspiration of oropharyngeal contents, particularly in individuals with impaired consciousness, dysphagia, or poor dental hygiene. Conditions such as alcoholism, general anesthesia, seizures, and gastroesophageal reflux disease increase the risk of aspiration. Periodontal disease plays a major role by providing a source of anaerobic bacteria. Other risk factors include airway obstruction, immunocompromised states such as HIV or diabetes, and hematogenous spread from infections like right-sided endocarditis.
Pathophysiologically, microorganisms—most commonly anaerobic bacteria—enter the lung through aspiration and proliferate in areas with poor clearance. This leads to tissue necrosis and cavity formation. Less commonly, abscesses arise from septic emboli traveling through the bloodstream. The most frequent causative organisms include anaerobes such as Peptostreptococcus, Fusobacterium, Prevotella, and Bacteroides species, often in combination with aerobic bacteria. Aerobic pathogens include Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa, with resistant organisms such as MRSA being increasingly recognized.
Clinically, patients typically present with cough producing foul-smelling, purulent sputum, fever, and pleuritic chest pain. In chronic cases, symptoms may persist for weeks and include weight loss, fatigue, night sweats, and malaise. Physical examination may reveal tachycardia, tachypnea, and abnormal lung findings such as crackles, decreased breath sounds, or signs of consolidation. Digital clubbing may develop in longstanding disease.
Diagnosis involves laboratory and imaging studies. Blood tests often show leukocytosis, while sputum cultures may be inconclusive, especially for anaerobic infections. Chest imaging is essential, with radiographs typically showing a cavity with an air–fluid level. CT scanning provides better anatomical detail and helps identify underlying causes such as obstruction or malignancy. Additional procedures such as bronchoscopy or needle aspiration may be required in atypical or nonresponsive cases.
Treatment consists primarily of prolonged antibiotic therapy targeting both anaerobic and aerobic organisms. First-line regimens include clindamycin or beta-lactam/beta-lactamase inhibitor combinations such as ampicillin-sulbactam, followed by oral therapy once clinical improvement occurs. The duration of therapy may extend from several weeks to months, depending on radiologic resolution. Supportive measures such as postural drainage and pulmonary physiotherapy are important adjuncts. In cases unresponsive to medical therapy, percutaneous or surgical drainage may be necessary.
The prognosis is generally good with appropriate treatment, although mortality ranges from 5% to 15%. Poor prognostic factors include large cavity size, delayed diagnosis, underlying comorbidities, and infection with resistant organisms. Complications may include empyema, massive hemoptysis, pneumothorax, and dissemination leading to conditions such as brain abscess. Careful follow-up with serial imaging is required to ensure resolution of the infection.
